DexCom (DXCM) Competitors $77.80 +1.39 (+1.82%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DXCM vs. MDT, BDX, EW, IDXX, RMD, STE, PODD, HOLX, BAX, and GMEDShould you be buying DexCom stock or one of its competitors? The main competitors of DexCom include Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry. DexCom vs. Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed STERIS Insulet Hologic Baxter International Globus Medical Medtronic (NYSE:MDT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Does the media favor MDT or DXCM? In the previous week, Medtronic had 4 more articles in the media than DexCom. MarketBeat recorded 29 mentions for Medtronic and 25 mentions for DexCom. Medtronic's average media sentiment score of 1.01 beat DexCom's score of 0.86 indicating that Medtronic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medtronic 17 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 13 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk & volatility, MDT or DXCM? Medtronic has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Which has preferable earnings & valuation, MDT or DXCM? Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedtronic$33.00B3.16$3.68B$3.2724.88DexCom$3.95B7.69$541.50M$1.6746.59 Is MDT or DXCM more profitable? DexCom has a net margin of 17.22% compared to Medtronic's net margin of 13.00%. DexCom's return on equity of 31.40% beat Medtronic's return on equity.Company Net Margins Return on Equity Return on Assets Medtronic13.00% 13.79% 7.62% DexCom 17.22%31.40%10.58% Do analysts rate MDT or DXCM? Medtronic currently has a consensus price target of $95.27, indicating a potential upside of 17.08%. DexCom has a consensus price target of $98.00, indicating a potential upside of 25.96%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Medtronic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medtronic 1 Sell rating(s) 9 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.41DexCom 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72 Does the MarketBeat Community favor MDT or DXCM? Medtronic received 613 more outperform votes than DexCom when rated by MarketBeat users. Likewise, 75.64% of users gave Medtronic an outperform vote while only 71.72% of users gave DexCom an outperform vote. CompanyUnderperformOutperformMedtronicOutperform Votes158775.64% Underperform Votes51124.36% DexComOutperform Votes97471.72% Underperform Votes38428.28% Do institutionals & insiders have more ownership in MDT or DXCM? 82.1% of Medtronic shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.2% of Medtronic shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryDexCom beats Medtronic on 11 of the 18 factors compared between the two stocks. Ad DTIWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!Click here to get the details. Get DexCom News Delivered to You Automatically Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXCM vs. The Competition Export to ExcelMetricDexComSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.39B$4.41B$5.14B$9.31BDividend YieldN/A44.87%4.81%4.06%P/E Ratio46.5924.95135.1817.53Price / Sales7.6946.561,235.42140.39Price / Cash38.8944.2040.6537.95Price / Book14.547.254.884.92Net Income$541.50M$13.83M$118.97M$225.78M7 Day Performance-3.32%-2.91%16.19%-1.58%1 Month Performance2.01%3.03%16.02%6.67%1 Year Performance-36.93%47.13%34.95%22.48% DexCom Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXCMDexCom4.9889 of 5 stars$77.80+1.8%$98.00+26.0%-36.5%$30.39B$3.95B46.599,600Short Interest ↓MDTMedtronic4.9716 of 5 stars$82.04-0.5%$95.27+16.1%-1.5%$105.20B$33.00B25.1495,000Options VolumePositive NewsBDXBecton, Dickinson and Company4.9806 of 5 stars$230.50+2.2%$283.50+23.0%-4.8%$66.64B$20.18B37.9774,000Short Interest ↓EWEdwards Lifesciences4.0018 of 5 stars$73.84+0.7%$79.40+7.5%-3.6%$43.55B$6.00B10.7419,800Analyst UpgradeInsider TradeAnalyst RevisionIDXXIDEXX Laboratories4.991 of 5 stars$433.37+0.3%$539.63+24.5%-21.1%$35.49B$3.84B41.6711,000Positive NewsRMDResMed4.6286 of 5 stars$241.36+1.2%$227.91-5.6%+43.5%$35.43B$4.81B31.599,980Analyst RevisionPositive NewsSTESTERIS4.9501 of 5 stars$213.74-0.2%$262.50+22.8%-1.5%$21.10B$5.14B48.9118,179Positive NewsPODDInsulet4.3598 of 5 stars$266.78-1.0%$267.44+0.2%+27.2%$18.71B$1.70B46.123,000HOLXHologic4.686 of 5 stars$73.25-0.5%$89.50+22.2%+1.8%$16.62B$4.03B22.147,063Analyst RevisionBAXBaxter International4.632 of 5 stars$29.53-2.6%$40.45+37.0%-23.4%$15.08B$15.06B149.2060,000GMEDGlobus Medical4.957 of 5 stars$82.33-0.1%$92.18+12.0%+68.4%$11.21B$2.48B122.675,000Analyst ForecastShort Interest ↓Analyst Revision Related Companies and Tools Related Companies Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors ResMed Competitors STERIS Competitors Insulet Competitors Hologic Competitors Baxter International Competitors Globus Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DXCM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DXCM Stock Alerts